6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

L.Crinó; E.Dansin; P.Garrido Lopez; F.Griesinger; J.Laskin; N.Pavlakis; N.Thatcher; C.M.Tsai; D.Stroyakovskiy; W.C.Su

首页> 外文期刊>European Journal of Cancer Supplements >6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

【24h】

6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

机译：6594海报一线贝伐单抗联合化疗治疗晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者：一项开放性安全研究（MO19390）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
L.Crinó; E.Dansin; P.Garrido Lopez; F.Griesinger; J.Laskin; N.Pavlakis; N.Thatcher; C.M.Tsai; D.Stroyakovskiy; W.C.Su;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390) [J] . P.Garrido, N.Thatcher, L.Crino, European Journal of Cancer Supplements . 2009,第2期

机译：9170贝伐单抗（Bv）一线联合化疗对晚期或复发性非鳞状非小细胞肺癌（NSCLC）老年患者（pts）的安全性和有效性：SAiL（MO19390）
2. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). [J] . Laskin J, Crino L, Felip E, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第1期

机译：一线Bevacizumab Plus化疗在老年晚期或复发性非小细胞肺癌中的化疗的安全性和有效性：肺试验中Avastin的安全性（MO19390）。
3. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). [J] . Laskin J, Crino L, Felip E, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2012,第1期

机译：一线Bevacizumab Plus化疗在老年晚期或复发性非小细胞肺癌中的化疗的安全性和有效性：肺试验中Avastin的安全性（MO19390）。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. Open-label multicenter randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323 [O] . Toshiyuki Kozuki, Naoyuki Nogami, Osamu Hataji, 2020

机译：多西紫杉醇联合贝伐单抗或培美曲塞联合贝伐单抗的开放标签多中心II期随机研究用于治疗老年（≥75岁）先前未经治疗的晚期非鳞状非小细胞肺癌老年患者：TORG1323
7. P3-078: MO19390: an open-label safety study of bevacizumab in combination with chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) [O] . Crinó Lucio, Dansin Eric, Garrido Pilar, 2007

机译：P3-078：MO19390：贝伐单抗联合化疗作为晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者的一线治疗的开放性安全性研究

6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390)

著录项

相似文献

相关主题

期刊订阅